Abstract 1414P
Background
The aim of this study was to observe the concurrent genetic profiles of EGFR-mutated advanced Chinese non-small cell lung cancer (NSCLC), as well as to analyze the effects of diverse concurrent genetic alterations on the prognosis in EGFR-mutated NSCLC treated in first-line with EGFR-TKI.
Methods
The CAPTRA-Lung (NCT03334864) database was used to retrieve 307 patients with advanced EGFR-mutated NSCLC between January 1, 2018 and January 1, 2022 in our institution. Of those, 103 patients were detected by next-generation sequencing (NGS) and the results showed other concurrent genetic alterations. We divided them into two cohorts: those who were sequenced with NGS at baseline were included in cohort 1, and those who received NGS after progression to first-line therapy were contained in cohort 2. The follow-up deadline was October 1, 2022.
Results
The following genes are found to be most frequent in the entire cohort: TP53 mutation (n = 64, 62.14%), EGFR amplification (n = 14, 13.59%), KRAS mutation (n = 13, 12.62%), PIK3CA mutation (n = 13, 12.62%), and DNMT3A mutation (n = 13, 12.62%). Most of the TP53 mutations have been identified in exons 5 (16/64), 6 (9/64), 7 (10/64), 8(9/64), etc. For KRAS mutations, G12V (4/13) and G12S (3/13) were the most common mutation types, and E545K (5/13) and H1047R (2/13) were the most frequently alterations observed in PIK3CA. Cohort 1 constituted 68 patients (mean [SD] age, 60.93 [9.051] years; 55.9% female). Multivariate analysis demonstrated that alterations in TP53 (HR 1.946, 95% CI 1.112-3.403; P = 0.020) and MET (HR 3.581, 95% CI 1.070-11.992; P = 0.039) were independently correlated to poor progression-free survival (PFS). Cohort 2 encompassed 35 patients (mean [SD] age, 56.80 [8.741] years; 71.4% female). Multifactorial analysis showed that TP53 mutation (HR 2.198, 95% CI 1.006-4.803; P = 0.048) and RB1 mutation (HR 8.798, 95% CI 1.604-48.269; P = 0.012) were independent risk factors for PFS with first-line targeted therapy.
Conclusions
This research added to the evidence that co-alterations such as TP53, MET, and RB1 are prospective prognostic biomarkers in NSCLC patients treated with EGFR-TKI.
Clinical trial identification
NCT03334864.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1411P - Tusamitamab ravtansine plus ramucirumab as 2L therapy or beyond in patients with metastatic NSq NSCLC and high CEACAM5 expression (CARMEN-LC04)
Presenter: Grace Dy
Session: Poster session 20
1412P - SAKK 17/18-ORIGIN trial: Efficacy and safety from a multicenter phase II trial of gemcitabine and atezolizumab in patients with advanced NSCLC progressing on immune checkpoint inhibitors
Presenter: Alessandra Curioni-Fontecedro
Session: Poster session 20
1416P - Recurrence of infusion-related reaction (IRRs) associated to avimantamab
Presenter: Maria Virginia Sanchez Becerra
Session: Poster session 20
1417P - Change in healthcare resource use and associated costs of patients with metastatic lung cancer between 2013 and 2019: An observational study from the French national claims database
Presenter: Christos Chouaid
Session: Poster session 20
1418P - Impact of TTFields therapy on global and functional health-related quality of life (HRQoL) in metastatic non-small cell lung cancer (mNSCLC) from the pivotal LUNAR study
Presenter: Rupesh Kotecha
Session: Poster session 20
1419P - TACSTD2 (Trop-2) constitutes a promising antibody-drug conjugate target for patients with non-small cell lung cancer brain metastases
Presenter: Sara Hijazo-Pechero
Session: Poster session 20
1420P - Real-life management of octogenarians with NSCLC in a French nationwide cohort
Presenter: Romain Corre
Session: Poster session 20
1421P - AI-powered intracranial tumor response predicts systemic progression with high concordance in endpoint evaluation in the phase III CROWN study
Presenter: Shao-Lun Lu
Session: Poster session 20
1422P - Comprehensive genomic profiling (CGP) changes management and improves survival in patients with advanced non-small cell lung cancer (aNSCLC)
Presenter: George Simon
Session: Poster session 20